Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)

This prospective interventional clinical study evaluates the efficacy and safety of combining systemic chemotherapy followed by ablative stereotactic body radiotherapy (SBRT) as first-line treatment in adult patients with locally advanced, inoperable pancreatic cancer. The study aims to determine the response rate after SBRT delivered following initial chemotherapy, as well as time to disease progression and treatment-related toxicity. Patients receive standard first-line chemotherapy and, in the absence of disease progression, undergo ablative SBRT to the primary tumor, followed by continuat

Trial Details

NCT ID
NCT07407231
Phase
NA
Sponsor
Institute of Oncology Ljubljana
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Ablative Stereotactic Body Radiotherapy (SBRT)
  • Standard First-Line Chemotherapy
Locations (sample)
  • Ljubljana, Slovenia|46.05108,14.50513

Key Eligibility Criteria

  • Adults aged 18 years and older
  • Locally advanced, inoperable pancreatic cancer
  • Treated with first-line systemic chemotherapy followed by stereotactic body radiotherapy (SBRT) at participating centers
  • Ability to provide written informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →